Key facts
- It has raised $70K; the latest was Seed Round ($70K) in Jan 2026.
- Notable investors include Startup Wise Guys, Tehnopol Startup Incubator, Taavi Tamkivi, Alver Lumberg, Kristel Kruustük — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Scrubin
- ·The full record, as it builds
Funding rounds
No funding rounds for Scrubin are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Scrubin
Developer of clinical evidence search technology designed to support healthcare professionals in accessing reliable medical information. The company's platform aggregates cited clinical data from guidelines, trials, and regulatory sources, applies systematic reviews, supports queries on treatment options, drug information, diagnostics, and lab workups, enabling doctors, nurses, and healthcare institutions to obtain trustworthy evidence that improves decision-making, enhances patient care, reduces fragmented research reliance, and maintains compliance with medical standards.
- Sector
- Healthcare
- HQ
- Tallinn, Estonia
- Founded
- 2023
- Employees
- 3
- Website
- scrubin.io/
- Ownership
- Privately Held (backing)
Scrubin doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Scrubin shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Scrubin in its N-PORT filings yet. We sweep new filings monthly.